0001683168-19-003656.txt : 20191115 0001683168-19-003656.hdr.sgml : 20191115 20191114173529 ACCESSION NUMBER: 0001683168-19-003656 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20191115 DATE AS OF CHANGE: 20191114 EFFECTIVENESS DATE: 20191115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KOP Therapeutics Corp. CENTRAL INDEX KEY: 0001793824 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-353470 FILM NUMBER: 191221814 BUSINESS ADDRESS: STREET 1: SUITE 404 - 815 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6Z 2E6 BUSINESS PHONE: 6047718332 MAIL ADDRESS: STREET 1: SUITE 404 - 815 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6Z 2E6 D 1 primary_doc.xml X0708 D LIVE 0001793824 KOP Therapeutics Corp. SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 6047718332 BRITISH COLUMBIA, CANADA KOP Industries Ltd. None Corporation true 2018 Tibor Fancis Gajdics SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Executive Officer Director Mark Richard Redcliffe SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Executive Officer Director Marco Andres Strub SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Director The proceeds will be used for research and development and general corporate and working capital purposes. Ian Hollis Mann SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Director Biotechnology No Revenues 06c false 2019-10-22 false true true false 0 114630 114630 0 The three sales in the U.S. totled $150,000 Canadian dollars. The Bank of Canada exchange rate on October 22, 2019, was 1 CAD = 0.7642 USD. Accordingly, the Company received US $114,630. false 3 0 0 0 The proceeds will be used for research and develop,emnt and general corporate and working capital purposes. false KOP Therapeutics Corp. /s/ Tibor Gajdics Tibor Gajdics President 2019-11-12